Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Where can you publish?
Find journals in COLORADO Profiles by department and year.

Contact Us
If you have any questions or feedback please contact us.

Michael D Iseman

TitleAffiliate - NJH
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Address12700 East 19th Avenue - Mail Stop 8619
Aurora CO 80045

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bishwakarma R, Kinney WH, Honda JR, Mya J, Strand MJ, Gangavelli A, Bai X, Ordway DJ, Iseman MD, Chan ED. Epidemiologic link between tuberculosis and cigarette/biomass smoke exposure: Limitations despite the vast literature. Respirology. 2015 May; 20(4):556-68.
      View in: PubMed
    2. Canham EM, Iseman MD. Guillain-Barré syndrome related to pulmonary tuberculosis. Ann Am Thorac Soc. 2014 Jun; 11(5):855-7.
      View in: PubMed
    3. Ovrutsky AR, Merkel PA, Schonteich E, Bai X, Kinney W, Iseman MD, Kartalija M, Knight V, Chan ED. Patients with non-tuberculous mycobacterial lung disease have elevated transforming growth factor-beta following ex vivo stimulation of blood with live Mycobacterium intracellulare. Scand J Infect Dis. 2013 Sep; 45(9):711-4.
      View in: PubMed
    4. Winthrop KL, Iseman M. Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nat Rev Rheumatol. 2013 Sep; 9(9):524-31.
      View in: PubMed
    5. Chan ED, Iseman MD. Surgery for MDR-TB? Int J Tuberc Lung Dis. 2013 May; 17(5):710.
      View in: PubMed
    6. Ovrutsky AR, Chan ED, Kartalija M, Bai X, Jackson M, Gibbs S, Falkinham JO, Iseman MD, Reynolds PR, McDonnell G, Thomas V. Cooccurrence of free-living amoebae and nontuberculous Mycobacteria in hospital water networks, and preferential growth of Mycobacterium avium in Acanthamoeba lenticulata. Appl Environ Microbiol. 2013 May; 79(10):3185-92.
      View in: PubMed
    7. Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med. 2013 Feb; 34(1):110-23.
      View in: PubMed
    8. Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, Strand MJ, Bai X, Ramamoorthy P, Rothman MS, Nagabhushanam V, McDermott M, Levin AR, Frazer-Abel A, Giclas PC, Korner J, Iseman MD, Shapiro L, Chan ED. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med. 2013 Jan 15; 187(2):197-205.
      View in: PubMed
    9. Daley CL, Iseman M. Mycobacterium avium complex and lung cancer: chicken or egg? Both? J Thorac Oncol. 2012 Sep; 7(9):1329-30.
      View in: PubMed
    10. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8):e1001300.
      View in: PubMed
    11. Mauchley DC, Daley CL, Iseman MD, Mitchell JD. Pulmonary resection and lung transplantation for bronchiectasis. Clin Chest Med. 2012 Jun; 33(2):387-96.
      View in: PubMed
    12. van Ingen J, Boeree MJ, van Soolingen D, Iseman MD, Heifets LB, Daley CL. Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? Infect Genet Evol. 2012 Jun; 12(4):832-7.
      View in: PubMed
    13. van Ingen J, de Lange WC, Boeree MJ, Iseman MD, Daley CL, Heifets LB, Böttger EC, van Soolingen D. XDR tuberculosis. Lancet Infect Dis. 2011 Aug; 11(8):585.
      View in: PubMed
    14. Iseman MD. Mycobacterial infections in the era of modern biologic agents. Am J Med Sci. 2011 Apr; 341(4):278-80.
      View in: PubMed
    15. Shang S, Ordway D, Henao-Tamayo M, Bai X, Oberley-Deegan R, Shanley C, Orme IM, Case S, Minor M, Ackart D, Hascall-Dove L, Ovrutsky AR, Kandasamy P, Voelker DR, Lambert C, Freed BM, Iseman MD, Basaraba RJ, Chan ED. Cigarette smoke increases susceptibility to tuberculosis--evidence from in vivo and in vitro models. J Infect Dis. 2011 May 1; 203(9):1240-8.
      View in: PubMed
    16. Chan ED, Keane J, Iseman MD. Should cigarette smoke exposure be a criterion to treat latent tuberculous infection? Am J Respir Crit Care Med. 2010 Oct 15; 182(8):990-2.
      View in: PubMed
    17. Iseman MD, Good JT. Thomas L. Petty: extraordinary clinician, bold innovator, inspiring educator, loyal friend, world-class raconteur, and waltonesque angler. Chest. 2010 Jun; 137(6):1255-6.
      View in: PubMed
    18. Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2010 Sep 1; 182(5):614-26.
      View in: PubMed
    19. Chan ED, Iseman MD. Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease. Gend Med. 2010 Feb; 7(1):5-18.
      View in: PubMed
    20. Chan ED, Strand MJ, Iseman MD. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB. Clin Infect Dis. 2009 Mar 1; 48(5):e50-2.
      View in: PubMed
    21. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis. 2008 Dec; 21(6):587-95.
      View in: PubMed
    22. Iseman MD, Marras TK. The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2008 Nov 15; 178(10):999-1000.
      View in: PubMed
    23. Chan ED, Strand MJ, Iseman MD. Treatment outcomes in extensively resistant tuberculosis. N Engl J Med. 2008 Aug 7; 359(6):657-9.
      View in: PubMed
    24. Schwiesow JN, Iseman MD, Peloquin CA. Concomitant use of voriconazole and rifabutin in a patient with multiple infections. Pharmacotherapy. 2008 Aug; 28(8):1076-80.
      View in: PubMed
    25. Chan ED, Iseman MD. Significance of bronchiectasis in patients with alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2008 Jul 15; 178(2):208; author reply 208-9.
      View in: PubMed
    26. Iseman MD, Fischer A. Tumor necrosis factor-alpha at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine. Clin Infect Dis. 2008 Jun 1; 46(11):1741-2.
      View in: PubMed
    27. Falkinham JO, Iseman MD, de Haas P, van Soolingen D. Mycobacterium avium in a shower linked to pulmonary disease. J Water Health. 2008 Jun; 6(2):209-13.
      View in: PubMed
    28. Iseman MD. Extensively drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand. Clin Infect Dis. 2007 Dec 1; 45(11):1415-6.
      View in: PubMed
    29. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15; 175(4):367-416.
      View in: PubMed
    30. Chan ED, Kaminska AM, Gill W, Chmura K, Feldman NE, Bai X, Floyd CM, Fulton KE, Huitt GA, Strand MJ, Iseman MD, Shapiro L. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis. 2007; 39(8):690-6.
      View in: PubMed
    31. Iseman MD, Heifets LB. Rapid detection of tuberculosis and drug-resistant tuberculosis. N Engl J Med. 2006 Oct 12; 355(15):1606-8.
      View in: PubMed
    32. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 2005 Dec 15; 172(12):1487-90.
      View in: PubMed
    33. Chmura K, Chan ED, Noone PG, Zariwala M, Winn RA, Knowles MR, Iseman MD, Gardner EM. A middle-aged woman with recurrent respiratory infections. Respiration. 2005 Jul-Aug; 72(4):427-30.
      View in: PubMed
    34. Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, Brayshaw SJ, Huitt GA, Iseman MD, Saavedra MT, Taussig LM, Wagener JS, Accurso FJ, Nick JA. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2005 Mar 15; 171(6):621-6.
      View in: PubMed
    35. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004 Jun 1; 38(11):1538-44.
      View in: PubMed
    36. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004 May 15; 169(10):1103-9.
      View in: PubMed
    37. Fennelly K, Iseman MD. Etanercept or mycobacterium lung injury? Chest. 2003 Sep; 124(3):1174; author reply 1174-5.
      View in: PubMed
    38. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003 Feb 15; 167(4):603-62.
      View in: PubMed
    39. Iseman MD. A new approach to treating patients with MDR-TB? Int J Tuberc Lung Dis. 2002 Dec; 6(12):1037.
      View in: PubMed
    40. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ. 2002 Nov 30; 325(7375):1282-6.
      View in: PubMed
    41. Heifets L, Iseman MD. Leo Tolstoy, TB in Russia, and American perceptions. Int J Tuberc Lung Dis. 2002 Nov; 6(11):939-41.
      View in: PubMed
    42. Iseman MD. Medical management of pulmonary disease caused by Mycobacterium avium complex. Clin Chest Med. 2002 Sep; 23(3):633-41, vii.
      View in: PubMed
    43. Iseman MD, Petty TL. Not just another researcher. Nat Med. 2002 May; 8(5):426.
      View in: PubMed
    44. Iseman MD. Some healthy skepticism about inhaled therapy for tuberculosis. Clin Infect Dis. 2001 Jul 15; 33(2):266-7.
      View in: PubMed
    45. Chan ED, Kong PM, Fennelly K, Dwyer AP, Iseman MD. Vertebral osteomyelitis due to infection with nontuberculous Mycobacterium species after blunt trauma to the back: 3 examples of the principle of locus minoris resistentiae. Clin Infect Dis. 2001 May 15; 32(10):1506-10.
      View in: PubMed
    46. Berning SE, Cherry TA, Iseman MD. Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. Clin Infect Dis. 2001 Feb 15; 32(4):643-6.
      View in: PubMed
    47. Heifets L, Iseman MD. Are we on the brink of a new white plague in Russia? Int J Tuberc Lung Dis. 2000 Dec; 4(12):1095-6.
      View in: PubMed
    48. Chan ED, Heifets L, Iseman MD. Immunologic diagnosis of tuberculosis: a review. Tuber Lung Dis. 2000; 80(3):131-40.
      View in: PubMed
    49. Peloquin CA, Berning SE, Huitt GA, Iseman MD. AIDS and TB drug absorption. Int J Tuberc Lung Dis. 1999 Dec; 3(12):1143-4.
      View in: PubMed
    50. Chan ED, Iseman MD. Potential association between calcified thoracic lymphadenopathy due to previous Histoplasma capsulatum infection and pulmonary Mycobacterium avium complex disease. South Med J. 1999 Jun; 92(6):572-6.
      View in: PubMed
    51. Fennelly KP, Iseman MD. Health care workers and tuberculosis: the battle of a century. Int J Tuberc Lung Dis. 1999 May; 3(5):363-4.
      View in: PubMed
    52. Iseman MD. Treatment and implications of multidrug-resistant tuberculosis for the 21st century. Chemotherapy. 1999; 45 Suppl 2:34-40.
      View in: PubMed
    53. Iseman MD. Management of multidrug-resistant tuberculosis. Chemotherapy. 1999; 45 Suppl 2:3-11.
      View in: PubMed
    54. Youngchaiyud P, Iseman MD. Update treatment of multidrug-resistant tuberculosis. Introduction, discussion and summary. Chemotherapy. 1999; 45 Suppl 2:1-2, 41-5.
      View in: PubMed
    55. Iseman MD. MDR-TB and the developing world--a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy. Int J Tuberc Lung Dis. 1998 Nov; 2(11):867.
      View in: PubMed
    56. Peloquin CA, Berning SE, Huitt GA, Iseman MD. Levofloxacin for drug-resistant Mycobacterium tuberculosis. Ann Pharmacother. 1998 Feb; 32(2):268-9.
      View in: PubMed
    57. Iseman MD. An unholy trinity--three negative sputum smears and release from tuberculosis isolation. Clin Infect Dis. 1997 Sep; 25(3):671-2.
      View in: PubMed
    58. Berning SE, Iseman MD. Rifamycin-induced lupus syndrome. Lancet. 1997 May 24; 349(9064):1521-2.
      View in: PubMed
    59. Pomerantz M, Denton JR, Huitt GA, Brown JM, Powell LA, Iseman MD. Resection of the right middle lobe and lingula for mycobacterial infection. Ann Thorac Surg. 1996 Oct; 62(4):990-3.
      View in: PubMed
    60. Peloquin CA, Nitta AT, Berning SE, Iseman MD, James GT. Pharmacokinetic evaluation of thiacetazone. Pharmacotherapy. 1996 Sep-Oct; 16(5):735-41.
      View in: PubMed
    61. Iseman MD, Goble M. Multidrug-resistant tuberculosis. N Engl J Med. 1996 Jan 25; 334(4):267; author reply 268-9.
      View in: PubMed
    62. Elliott AM, Berning SE, Iseman MD, Peloquin CA. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis. 1995 Oct; 76(5):463-7.
      View in: PubMed
    63. Berning SE, Madsen L, Iseman MD, Peloquin CA. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med. 1995 Jun; 151(6):2006-9.
      View in: PubMed
    64. Iseman MD, Starke J. Immigrants and tuberculosis control. N Engl J Med. 1995 Apr 20; 332(16):1094-5.
      View in: PubMed
    65. Peloquin CA, James GT, Craig LD, Kim M, McCarthy EA, Iklé D, Iseman MD. Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid prodrug. Pharmacotherapy. 1994 Jul-Aug; 14(4):415-23.
      View in: PubMed
    66. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993 Sep 9; 329(11):784-91.
      View in: PubMed
    67. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med. 1993 Feb 25; 328(8):576-8.
      View in: PubMed
    68. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993 Feb 25; 328(8):527-32.
      View in: PubMed
    69. Nitta AT, Iseman MD, Newell JD, Madsen LA, Goble M. Ten-year experience with artificial pneumoperitoneum for end-stage, drug-resistant pulmonary tuberculosis. Clin Infect Dis. 1993 Feb; 16(2):219-22.
      View in: PubMed
    70. Cohn DL, Iseman MD. Treatment and prevention of multidrug-resistant tuberculosis. Res Microbiol. 1993 Feb; 144(2):150-3.
      View in: PubMed
    71. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med. 1992 Dec 17; 327(25):1817-8.
      View in: PubMed
    72. Nardell EA, Iseman MD, Kubica G, Riley RL, Stead WW, Urbach F. Multidrug-resistant tuberculosis. N Engl J Med. 1992 Oct 15; 327(16):1173-4.
      View in: PubMed
    73. Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis. 1991 Oct; 144(4):914-6.
      View in: PubMed
    74. Heifets LB, Iseman MD. Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections. Am Rev Respir Dis. 1991 Jul; 144(1):1-2.
      View in: PubMed
    75. Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis. 1990 Dec; 142(6 Pt 1):1301-5.
      View in: PubMed
    76. Heifets LB, Iseman MD. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N Engl J Med. 1990 Aug 9; 323(6):419-20.
      View in: PubMed
    77. Iseman MD, Madsen L, Goble M, Pomerantz M. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am Rev Respir Dis. 1990 Mar; 141(3):623-5.
      View in: PubMed
    78. Iseman MD. Mycobacterium avium complex and the normal host: the other side of the coin. N Engl J Med. 1989 Sep 28; 321(13):896-8.
      View in: PubMed
    79. Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin Chest Med. 1989 Sep; 10(3):341-53.
      View in: PubMed
    80. Gangadharam PR, Perumal VK, Parikh K, Podapati NR, Taylor R, Farhi DC, Iseman MD. Susceptibility of beige mice to Mycobacterium avium complex infections by different routes of challenge. Am Rev Respir Dis. 1989 May; 139(5):1098-104.
      View in: PubMed
    81. Iseman MD. Synergism: the Rosetta stone for Mycobacterium avium complex chemotherapy? Am Rev Respir Dis. 1988 Oct; 138(4):767-8.
      View in: PubMed
    82. Gangadharam PR, Perumal VK, Podapati NR, Kesavalu L, Iseman MD. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother. 1988 Sep; 32(9):1400-3.
      View in: PubMed
    83. Heifets LB, Lindholm-Levy PJ, Iseman MD. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis. 1988 Mar; 137(3):719-21.
      View in: PubMed
    84. Heifets LB, Iseman MD, Lindholm-Levy PJ. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects. Am Rev Respir Dis. 1988 Mar; 137(3):711-5.
      View in: PubMed
    85. Iseman MD, Goble M. Treatment of tuberculosis. Adv Intern Med. 1988; 33:253-65.
      View in: PubMed
    86. Gangadharam PR, Perumal VK, Jairam BT, Rao PN, Nguyen AK, Farhi DC, Iseman MD. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis. 1987 Aug; 136(2):329-33.
      View in: PubMed
    87. Horsburgh CR, Mason UG, Heifets LB, Southwick K, Labrecque J, Iseman MD. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis. 1987 Feb; 135(2):418-21.
      View in: PubMed
    88. Heifets LB, Iseman MD, Lindholm-Levy PJ. Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. Drugs Exp Clin Res. 1987; 13(9):529-38.
      View in: PubMed
    89. Heifets LB, Iseman MD, Crowle AJ, Lindholm-Levy PJ. Pyrazinamide is not active in vitro against Mycobacterium avium complex. Am Rev Respir Dis. 1986 Dec; 134(6):1287-8.
      View in: PubMed
    90. Heifets LB, Iseman MD, Lindholm-Levy PJ. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1986 Dec; 30(6):927-32.
      View in: PubMed
    91. Horsburgh CR, Cohn DL, Roberts RB, Masur H, Miller RA, Tsang AY, Iseman MD. Mycobacterium avium-M. intracellulare isolates from patients with or without acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1986 Dec; 30(6):955-7.
      View in: PubMed
    92. Perumal VK, Gangadharam PR, Heifets LB, Iseman MD. Dynamic aspects of the in vitro chemotherapeutic activity of ansamycin (rifabutine) on mycobacterium intracellulare. Am Rev Respir Dis. 1985 Dec; 132(6):1278-80.
      View in: PubMed
    93. Heifets LB, Iseman MD, Lindholm-Levy PJ, Kanes W. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agents Chemother. 1985 Oct; 28(4):570-5.
      View in: PubMed
    94. Heifets LB, Iseman MD. Determination of in vitro susceptibility of mycobacteria to ansamycin. Am Rev Respir Dis. 1985 Sep; 132(3):710-1.
      View in: PubMed
    95. Iseman MD, Sbarbaro JA. Tuberculoid bacilli and tuberculoidosis. Chest. 1985 Aug; 88(2):316-7.
      View in: PubMed
    96. Heifets LB, Iseman MD. Radiometric method for testing susceptibility of mycobacteria to pyrazinamide in 7H12 broth. J Clin Microbiol. 1985 Feb; 21(2):200-4.
      View in: PubMed
    97. Iseman MD, Corpe RF, O'Brien RJ, Rosenzwieg DY, Wolinsky E. Disease due to Mycobacterium avium-intracellulare. Chest. 1985 Feb; 87(2 Suppl):139S-149S.
      View in: PubMed
    98. Horsburgh CR, Mason UG, Farhi DC, Iseman MD. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine (Baltimore). 1985 Jan; 64(1):36-48.
      View in: PubMed
    99. Heifets LB, Iseman MD, Cook JL, Lindholm-Levy PJ, Drupa I. Determination of in vitro susceptibility of Mycobacterium tuberculosis to cephalosporins by radiometric and conventional methods. Antimicrob Agents Chemother. 1985 Jan; 27(1):11-5.
      View in: PubMed
    100. Iseman MD. Clinically-derived mycobacterial classifications. Chest. 1984 May; 85(5):714-5.
      View in: PubMed
    101. Good JT, Iseman MD, Davidson PT, Lakshminarayan S, Sahn SA. Tuberculosis in association with pregnancy. Am J Obstet Gynecol. 1981 Jul 1; 140(5):492-8.
      View in: PubMed
    102. Iseman MD. Tuberculosis in the elderly: treating the "white plague". Geriatrics. 1980 Mar; 35(3):90-107.
      View in: PubMed
    Iseman's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
    Physical Neighbors
    _

    Copyright © 2012 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.5.1)